- Home
- RZLT vs ZBIO Comparison
RZLT vs ZBIO Comparison
Compare RZLT & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLT
- ZBIO
- Stock Information
- Founded
- RZLT 2010
- ZBIO 2019
- Country
- RZLT United States
- ZBIO United States
- Employees
- RZLT N/A
- ZBIO N/A
- Industry
- RZLT Biotechnology: Pharmaceutical Preparations
- ZBIO
- Sector
- RZLT Health Care
- ZBIO
- Exchange
- RZLT Nasdaq
- ZBIO NYSE
- Market Cap
- RZLT 226.4M
- ZBIO 268.7M
- IPO Year
- RZLT N/A
- ZBIO 2024
- Fundamental
- Price
- RZLT $3.53
- ZBIO $8.43
- Analyst Decision
- RZLT Strong Buy
- ZBIO Strong Buy
- Analyst Count
- RZLT 8
- ZBIO 6
- Target Price
- RZLT $12.00
- ZBIO $31.83
- AVG Volume (30 Days)
- RZLT 364.9K
- ZBIO 131.2K
- Earning Date
- RZLT 05-14-2025
- ZBIO 03-25-2025
- Dividend Yield
- RZLT N/A
- ZBIO N/A
- EPS Growth
- RZLT N/A
- ZBIO N/A
- EPS
- RZLT N/A
- ZBIO N/A
- Revenue
- RZLT N/A
- ZBIO $5,000,000.00
- Revenue This Year
- RZLT N/A
- ZBIO N/A
- Revenue Next Year
- RZLT N/A
- ZBIO N/A
- P/E Ratio
- RZLT N/A
- ZBIO N/A
- Revenue Growth
- RZLT N/A
- ZBIO N/A
- 52 Week Low
- RZLT $1.68
- ZBIO $5.83
- 52 Week High
- RZLT $6.19
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- RZLT 33.06
- ZBIO N/A
- Support Level
- RZLT $3.53
- ZBIO N/A
- Resistance Level
- RZLT $3.81
- ZBIO N/A
- Average True Range (ATR)
- RZLT 0.25
- ZBIO 0.00
- MACD
- RZLT -0.03
- ZBIO 0.00
- Stochastic Oscillator
- RZLT 16.53
- ZBIO 0.00
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.